Showing results (71-80 of 167) with videos related to
Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)E Mamounas, S Wieand, N Wolmark, et al.Journal of Hypertension|April 1, 1991
Twenty-four-hour ambulatory blood pressure in men and women aged 17 to 80 years: the Allied Irish Bank StudyE O'Brien, J Murphy, A Tyndall, et al.Cancer|May 27, 2003
Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the communityJane T Hickok, Joseph A Roscoe, Gary R Morrow, et al.Cancer Chemotherapy and Pharmacology|January 1, 1985
Phase II trial of vincristine infusion in acute leukemiaD V Jackson, A R Chauvenet, R D Callahan, et al.Substance Use & Misuse|May 2, 2022
Harm Reduction Policy Support among Students at Two U.S. UniversitiesBarbara Andraka-Christou, Thuy Nguyen, Shana Harris, et al.Biochemical and Biophysical Research Communications|April 25, 2000
Emx1-specific expression of foreign genes using "knock-in" approachX L Jin, H Guo, C Mao, et al.Journal of Human Hypertension|June 1, 1988
The antihypertensive efficacy of verapamil in the elderly evaluated by ambulatory blood pressure measurementJ P Cox, C A O'Boyle, F Mee, et al.Cancer|February 22, 2002
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B studyEllis G Levine, Susan Halabi, John D Roberts, et al.American Journal of Epidemiology|August 15, 1992
The increase in blood pressure with age and body mass index is overestimated by conventional sphygmomanometryJ Staessen, E O'Brien, N Atkins, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 27, 2006
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902C M Rocha-Lima, J E Herndon, M E Lee, et al.Pageof 17